04 Jun 2021 Stockhead Actinogen to progress Alzheimer’s study
02 Jun 2021 The Market Herald Actinogen Medical (ASX:ACW) granted ethics committee approval for Alzheimers study
02 Jun 2021 Biotech Daily Actinogen: Part-A Xanamia Xanamem Cognition Trial Approved
07 May 2021 180 Markets 18 Minutes with Actinogen MD Steven Gourlay
30 Apr 2021 Actinogen Strategic Update Teleconference Transcript
22 Apr 2021 Biotech Daily Actinogen Plans Three Phase II Cognition Trials For 2022
21 Apr 2021 Daily Motion / Australian Business News Actinogen undervalued by the market
21 Apr 2021 Actinogen Actinogen Strategic Update and Investor Presentation
21 Apr 2021 Ausbiz Actinogen undervalued by the market
15 Apr 2021 The Motley Fool Actinogen (ASX:ACW) share price surges 23% today, 165% this year
15 Mar 2021 Biotech Daily Actinogen Appoints Dr Steven Gourlay CEO On $400k
15 Mar 2021 The Market Herald Actinogen Medical (ASX:ACW) appoints new CEO
11 Feb 2021 Biotech Daily Actinogen Shortfall Raises $3.55m – Total $10.9m
05 Feb 2021 The Market Herald Actinogen (ASX:ACW) nabs FDA designation for Fragile X treatment
01 Dec 2020 Switzer TV Actinogen Medical CEO Dr Bill Ketelbey speaks at the Switzer Small and Micro Cap Virtual Investor Day 2020
27 Nov 2020 Open Briefing Actinogen Annual General Meeting 27 Nov 2020: Webcast presentation
27 Nov 2020 Actinogen Actinogen Annual General Meeting 27 Nov 2020: Audio only
27 Nov 2020 Actinogen Actinogen Annual General Meeting 27 Nov 2020: AGM Presentations
20 Nov 2020 Biotech Daily Dr Boreham’s Crucible: Actinogen Medical
13 Nov 2020 Biotech Daily Actinogen Rights Raise $1.4m Of Hoped-For $4.9m – Total $7.4m
09 Nov 2020 The Market Herald Actinogen Medical (ASX:ACW) files new patent applications
09 Nov 2020 The Motley Fool Actinogen Medical (ASX:ACW) share price jumps on patent news
09 Nov 2020 Fintech Inshorts Actinogen Medical: Files New Patent Applications
09 Nov 2020 Finance News Network Actinogen Medical (ASX:ACW) tackling Alzheimer’s by inhibiting excess cortisol production in the brain
03 Nov 2020 The Market Herald Actinogen Medical (ASX:ACW) to test Fragile X syndrome treatment in Melbourne clinical trial WATCH FROM 4:50 to 13:33
02 Nov 2020 Boardroom Media ASX: ACW World first medical trial Fragile X Syndrome
02 Nov 2020 Actinogen Actinogen presentation: New clinical development opportunity Fragile X syndrome (Nov 2020)
29 Oct 2020 Monsoon Communications Monsoon Morning Twilight Investor Briefing webinar video (28 Oct 2020) – watch from 17:50 Dr Bill Ketelbey provided a clinical development update
28 Oct 2020 Actinogen Monsoon Morning Twilight Investor Briefing (28 Oct 2020) Actinogen presentation
23 Oct 2020 Fragile X News Today Phase 2 Trial Planned for Xanamem, Oral Treatment for Fragile X
19 Oct 2020 Actinogen Actinogen Medical Conference Call 19 Oct 2020: Audio only
19 Oct 2020 Actinogen Actinogen Conference Call 19 Oct 2020: Webcast presentation
19 Oct 2020 Bioshares Edition 865: Actinogen Sets Clear Direction with Capital Raise
15 Oct 2020 Biotech Daily Actinogen Up-To $11m Capital Raising For Xanamem Trials
15 Oct 2020 The Market Herald Actinogen Medical (ASX:ACW) to begin two clinical trials, $10.9M capital raise
15 Oct 2020 Stockhead Actinogen reveals its next clinical trial plans
15 Oct 2020 Investing.com BRIEF-Actinogen Medical Announces Two Clinical Trials
13 Oct 2020 Financial Review Bell Potter raising for Alzheimer’s drug hopeful Actinogen
13 Oct 2020 The Age As it happened: ASX misses 6200, but gains 1% 11.13am Actinogen in trading halt ahead of raise announcement
13 Oct 2020 The Market Herald Actinogen Medical (ASX:ACW) flags future capital raise
29 Sep 2020 Biotech Dispatch Actinogen Medical announces the appointment of new CFO
08 Sep 2020 ASX ASX Small & Mid-Cap Conference (8-10 Sep 2020): Actinogen pre-recorded presentation with Dr Bill Ketelbey
08 Sep 2020 Actinogen ASX Small & Mid-Cap Conference (8-10 Sep 2020): Actinogen investor presentation
31 Jul 2020 Actinogen Alzheimer’s Association International Conference (AAIC) Virtual Event (27-31 Jul 2020) Poster presentation by Prof Craig Ritchie, Chair of Actinogen Xanamem Clinical Advisory Board on behalf of Actinogen “Drug Development Summary for Xanamem™, a Potent Inhibitor of the 11β-HSD1 Enzyme”
31 Jul 2020 Finance News Network FNN CEO Showcase: Actinogen (ASX:ACW) Presentation, FNN Online Investor Event, July 2020
17 Jul 2020 Innovation Intelligence Alzheimer’s treatment could be worth $10bn annually
15 Jul 2020 Actinogen Bio Digital 2020: Company presentation and audio
08 Jun 2020 Actinogen Bio Digital 2020: Company presentation
08 Jun 2020 Actinogen BIO Digital 2020: Company presentation for partnering meetings
29 Apr 2020 Actinogen AAT/AD-PD 2020: Actinogen Full Presentation with Audio presented by Professor Craig Ritchie, Chair of Actinogen’s Xanamem Clinical Advisory Board. Chronically elevated cortisol and cognitive impairment: The therapeutic potential of Xanamem, a potent inhibitor of the 11β-HSD1 enzyme

Back
to top